- Home
- MASK vs RNXT Comparison
MASK vs RNXT Comparison
Compare MASK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASK
- RNXT
- Stock Information
- Founded
- MASK 2017
- RNXT 2012
- Country
- MASK China
- RNXT United States
- Employees
- MASK N/A
- RNXT N/A
- Industry
- MASK
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- MASK
- RNXT Health Care
- Exchange
- MASK NYSE
- RNXT Nasdaq
- Market Cap
- MASK 31.7M
- RNXT 31.6M
- IPO Year
- MASK 2025
- RNXT 2021
- Fundamental
- Price
- MASK $2.70
- RNXT $1.15
- Analyst Decision
- MASK
- RNXT Strong Buy
- Analyst Count
- MASK 0
- RNXT 1
- Target Price
- MASK N/A
- RNXT $9.00
- AVG Volume (30 Days)
- MASK 98.9K
- RNXT 195.7K
- Earning Date
- MASK 01-01-0001
- RNXT 03-31-2025
- Dividend Yield
- MASK N/A
- RNXT N/A
- EPS Growth
- MASK 55.43
- RNXT N/A
- EPS
- MASK 0.15
- RNXT N/A
- Revenue
- MASK $4,561,963.00
- RNXT N/A
- Revenue This Year
- MASK N/A
- RNXT N/A
- Revenue Next Year
- MASK N/A
- RNXT N/A
- P/E Ratio
- MASK $17.12
- RNXT N/A
- Revenue Growth
- MASK 172.95
- RNXT N/A
- 52 Week Low
- MASK $2.50
- RNXT $0.77
- 52 Week High
- MASK $3.99
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- MASK N/A
- RNXT 58.08
- Support Level
- MASK N/A
- RNXT $1.32
- Resistance Level
- MASK N/A
- RNXT $1.40
- Average True Range (ATR)
- MASK 0.00
- RNXT 0.11
- MACD
- MASK 0.00
- RNXT 0.00
- Stochastic Oscillator
- MASK 0.00
- RNXT 39.47
About MASK 3 E NETWORK TECHNOLOGY GROUP LTD
3 E Network Technology Group Ltd is a business-to-business ("B2B") information technology ("IT") business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.